RAMM Pharma selected as COVID-19 vaccine fulfilment partner by Uruguayan Ministry of Health
RAMM's GMP certified formulation facility is situated within close proximity to an airport and other distribution hubs.
Alcohol & Cannabis
TORONTO — RAMM Pharma Corp., a cannabinoid pharmaceutical products company, announces that the Uruguayan Ministry of Public Health, (Ministerio de Salúd Publica or “MSP”) has selected RAMM as a fulfilment and distribution partner for Uruguay’s COVID-19 vaccination program. Under the arrangement, RAMM will be responsible for the sterilization, packaging and distribution of syringes and other medical supplies for use in the country’s COVID-19 vaccination program. RAMM’s GMP certified pharmaceutical facility was selected for the program upon satisfaction of the requirements of the Ministry of Public Health.
“We are pleased to play an integral role in Uruguay’s COVID-19 vaccination effort. Our selection by the Ministry of Public Health is a testament to our longstanding relationship and recognition of the specialized capabilities of our team and GMP facility within the pharmaceutical community,” stated Jack Burnett, Chief Executive Officer.
RAMM’s GMP certified formulation facility is situated within close proximity to an airport and other distribution hubs. The facility totals approximately 36,600 square feet and features dedicated cannabis and medical product laboratories, along with sterilization and packaging capabilities and storage/distribution facilities.
RAMM is a provider of medical and pharmaceutical products for the healthcare industry. Since it’s inception in 1988, RAMM’s wholly owned subsidiary Medic Plast SA has manufactured and supplied medical devices, antiseptic and sterile products and other medical supplies and continues to be a supplier to the medical community in Uruguay.